Research Article
Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography
Table 1
Baseline clinical characteristics in ivabradine group (IG) and control group (CG).
| | | IG | CG | value |
| | Men (%) | 100 (14) | 86 (12) | 0.48 | | Age (years) | 62.7 ± 8.8 | 61.8 ± 7.8 | 0.76 | | Caucasian (%) | 100 (14) | 100 (14) | 1 | | Previous myocardial infarction (%) | 14 (2) | 14 (2) | 1 | | Previous angina (%) | 14 (2) | 43 (6) | 0.20 | | Previous PCI (%) | 14 (2) | 14 (2) | 1 | | Previous CABG (%) | 0 | 0 | — | | Systemic hypertension (%) | 43 (6) | 71 (10) | 0.25 | | Smoke (%) | 71 (10) | 57 (8) | 0.69 | | Familial history of CAD (%) | 100 (14) | 86 (12) | 0.48 | | Dyslipidemia (%) | 57 (8) | 43 (6) | 0.70 | | Diabetes mellitus (%) | 0 | 29 (4) | 0.09 | | Peripheral artery disease (%) | 0 | 0 | — | | Previous stroke (%) | 0 | 0 | — | | Renal impairment (%) | 0 | 0 | — | | Creatinine (mg/dl) | 0.94 ± 0.15 | 0.85 ± 0.05 | 0.04 | | Previous bleeding (%) | 0 | 0 | | | Multivessel coronary artery disease (%) | 43 (6) | 50 (7) | 0.96 |
|
|
PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; CAD = coronary artery disease.
|
